» Articles » PMID: 27358855

Cancer Stem Cells: Progress and Challenges in Lung Cancer

Overview
Date 2016 Jul 1
PMID 27358855
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of a subpopulation of tumor cells with stem cell-like characteristics first in hematological malignancies and later in solid tumors has emerged into a novel field of cancer research. It has been proposed that this aberrant population of cells now called "cancer stem cells" (CSCs) drives tumor initiation, progression, metastasis, recurrence, and drug resistance. CSCs have been shown to have the capacity of self-renewal and multipotency. Adopting strategies from the field of stem cell research has aided in identification, localization, and targeting of CSCs in many tumors. Despite the huge progress in other solid tumors such as brain, breast, and colon cancers no substantial advancements have been made in lung cancer. This is most likely due to the current rudimentary understanding of lung stem cell hierarchy and heterogeneous nature of lung disease. In this review, we will discuss the most recent findings related to identification of normal lung stem cells and CSCs, pathways involved in regulating the development of CSCs, and the importance of the stem cell niche in development and maintenance of CSCs. Additionally, we will examine the development and feasibility of novel CSC-targeted therapeutic strategies aimed at eradicating lung CSCs.

Citing Articles

Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy.

Liu X, Wang X, Wu X, Zhan S, Yang Y, Jiang C Stem Cell Res Ther. 2025; 16(1):29.

PMID: 39876014 PMC: 11776311. DOI: 10.1186/s13287-025-04152-5.


Screening of Immune-related lncRNAs in Lung Adenocarcinoma and Establishing a Survival Prognostic Risk Prediction Model.

Jiang W, Zhu X, Bo J, Ma J Comb Chem High Throughput Screen. 2023; 27(8):1175-1190.

PMID: 37711103 DOI: 10.2174/1386207326666230913120523.


Advances in Lung Cancer Treatment Using Nanomedicines.

Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M ACS Omega. 2023; 8(1):10-41.

PMID: 36643475 PMC: 9835549. DOI: 10.1021/acsomega.2c04078.


Lung Cancer Stem Cells and Their Clinical Implications.

Rowbotham S, Goruganthu M, Arasada R, Wang W, Carbone D, Kim C Cold Spring Harb Perspect Med. 2021; 12(4).

PMID: 34580078 PMC: 9121890. DOI: 10.1101/cshperspect.a041270.


HIF-Prolyl Hydroxylase Domain Proteins (PHDs) in Cancer-Potential Targets for Anti-Tumor Therapy?.

Gaete D, Rodriguez D, Watts D, Sormendi S, Chavakis T, Wielockx B Cancers (Basel). 2021; 13(5).

PMID: 33673417 PMC: 7956578. DOI: 10.3390/cancers13050988.


References
1.
Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K . In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448(7151):318-24. DOI: 10.1038/nature05944. View

2.
Diaz A, Leon K . Therapeutic approaches to target cancer stem cells. Cancers (Basel). 2013; 3(3):3331-52. PMC: 3759198. DOI: 10.3390/cancers3033331. View

3.
Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

4.
Haegel H, Dierich A, Ceredig R . CD44 in differentiated embryonic stem cells: surface expression and transcripts encoding multiple variants. Dev Immunol. 1994; 3(4):239-46. PMC: 2275938. DOI: 10.1155/1994/25484. View

5.
Westhoff B, Colaluca I, dArio G, Donzelli M, Tosoni D, Volorio S . Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009; 106(52):22293-8. PMC: 2799768. DOI: 10.1073/pnas.0907781106. View